Mr. Todd Shapiro reports
RHELION LIFE SCIENCES' WHOLLY OWNED SUBSIDIARY FILAMENT HEALTH ISSUED NEW UNITED STATES PATENT, EXTENDING THE BROADEST NATURAL PSILOCYBIN PATENT ESTATE
The United States Patent and Trademark Office has issued a new patent to Rhelion Life Sciences Corp.'s wholly owned subsidiary, Filament Health Corp., titled "Psychoactive Alkaloid Extraction and Composition with Inhibited Dephosphorylation."
The grant adds to what the company believes is the most extensive patent estate in natural psilocybin, spanning issued patents across the United States, Canada, Australia, Israel, Mexico and Europe, and covering extraction, purification, stabilization, standardized compositions and delivery.
That estate protects how PEX010 is made. PEX010 is produced using Filament's proprietary and patented extraction, purification and stabilization methods and is available in a standardized dosing range of one, five and 25 milligrams (mg) from a single drug candidate, with a 0.5 mg dose to follow, giving investigators consistent composition across every dose, every study and every research site.
PEX010, Filament Health's botanical psilocybin drug candidate, underscores Filament's position as a leading supplier of pharmaceutical grade natural psilocybin, supporting more than 80 academic and philanthropic research studies worldwide. On April 30, 2026, the company completed its previously announced acquisition of Filament Health, including its lead drug candidate, PEX010, and its patent portfolio, which now stands at 79 issued patents across 13 patent families following this grant.
About Rhelion Life Sciences Corp.
Rhelion Life Sciences is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary, Filament Health, the company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with leading institutions around the world.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.